Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pethidine + haloperidol is a combination of two pharmaceutical drugs, pethidine (also known as meperidine) and haloperidol. Pethidine is an opioid analgesic primarily used for the relief of moderate to severe pain, acting mainly as a mu-opioid receptor agonist to inhibit pain signaling in the central nervous system. Haloperidol is a first-generation (typical) antipsychotic that acts predominantly as an antagonist at dopamine D2 receptors in the brain, reducing dopaminergic neurotransmission and thereby exerting antipsychotic and antiemetic effects[1][3][5]. The combination has been used off-label for its sedative properties, particularly in settings such as palliative care or during childbirth to manage agitation, anxiety, or nausea alongside pain control. The sedative effects of both drugs are potentiated when combined, which can increase both efficacy and risk[9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pethidine + haloperidol.